Rothschild Investment LLC Sells 820 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Rothschild Investment LLC reduced its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 34.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,536 shares of the company’s stock after selling 820 shares during the quarter. Rothschild Investment LLC’s holdings in Teva Pharmaceutical Industries were worth $34,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Stifel Financial Corp boosted its position in shares of Teva Pharmaceutical Industries by 54.0% in the third quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock valued at $1,196,000 after acquiring an additional 23,283 shares during the period. Robeco Institutional Asset Management B.V. boosted its position in shares of Teva Pharmaceutical Industries by 7.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock valued at $10,983,000 after acquiring an additional 33,277 shares during the period. Thrivent Financial for Lutherans boosted its position in shares of Teva Pharmaceutical Industries by 21.8% in the third quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock valued at $4,046,000 after acquiring an additional 40,218 shares during the period. Sio Capital Management LLC bought a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at approximately $24,314,000. Finally, Pinnbrook Capital Management LP bought a new position in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $4,966,000. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Trading Up 1.1 %

TEVA stock opened at $16.79 on Thursday. The company has a market capitalization of $19.02 billion, a PE ratio of -11.58, a price-to-earnings-growth ratio of 1.44 and a beta of 0.71. Teva Pharmaceutical Industries Limited has a one year low of $12.51 and a one year high of $22.80. The company’s 50 day moving average price is $19.84 and its two-hundred day moving average price is $18.49. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares of the company’s stock, valued at $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.55% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on TEVA shares. UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Piper Sandler raised their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. Barclays lowered their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. Finally, StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $23.57.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.